LRMR - NASDAQ

Larimar Therapeutics, Inc.

LRMR·NASDAQ

$3.20

-3.0%

HealthcareBiotechnology

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$273.97M

EPS-2.2700

P/E Ratio-1.41

Earnings Date08/06/2026

lrmr

Total Equity

Last Annual Value

78.08M

3-Year CAGR

-11%

5-Year CAGR

-3%

10-Year CAGR

-7%

Adjust for Inflation

Larimar Therapeutics, Inc. Competitors Analysis of Total Equity

LRMR · NASDAQ

Company	Total Equity	CAGR 3Y	CAGR 5Y	CAGR 10Y
Larimar Therapeutics, Inc. NASDAQ:LRMR	78.08M	-1.5%	3.9%	-4.3%
Alector, Inc. NASDAQ:ALEC	30.65M	-38.9%	-36.7%	N/A
Editas Medicine, Inc. NASDAQ:EDIT	27.29M	-57.2%	-45.2%	-14.8%
LB Pharmaceuticals Inc Common Stock NASDAQ:LBRX	301.31M	N/A	N/A	N/A
Lyell Immunopharma, Inc. NASDAQ:LYEL	248.20M	-27.6%	-23.2%	N/A
Tenaya Therapeutics, Inc. NASDAQ:TNYA	123.27M	-4.0%	-15.0%	N/A
Voyager Therapeutics, Inc. NASDAQ:VYGR	196.08M	-6.0%	15.6%	3.7%
Replimune Group, Inc. NASDAQ:REPL	415.84M	-9.2%	-3.6%	N/A
Kyverna Therapeutics, Inc. NASDAQ:KYTX	232.28M	67.8%	N/A	N/A
Korro Bio, Inc. NASDAQ:KRRO	51.44M	-32.9%	-17.0%	N/A
Lexeo Therapeutics, Inc. Common Stock NASDAQ:LXEO	246.67M	29.5%	N/A	N/A

Larimar Therapeutics, Inc. Fair Value Envelope

LRMR · NASDAQ

Our analysis suggests that LRMR has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $3.2014, this represents a potential HIDDEN relative to our calculated worth for Larimar Therapeutics, Inc..

HIDDEN

Intrinsic Value

Current Price: $3.2014

Related Guides

Blog Categories

Continue your LRMR research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.